Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
Consumer
Eli Lilly announced it will acquire three privately held vaccine makers in deals totaling nearly $4 billion, marking a significant strategic pivot beyond its GLP-1 and oncology core. The diversification move raises near-term integration and capital allocation concerns while potentially expanding Lilly's long-run revenue base, but the strategic payoff is years away.
0 reads·0 theses
Angle
↓ SHORT-5% target+3% stop2-4 weeks
Fade the LLY pop — $4B vaccine diversification spend at stretched valuation with insiders selling and no near-term revenue catalyst argues for a tactical short or underweight versus peers.